The Antiallergic Mast Cell Stabilizers Lodoxamide and Bufrolin as the First High and Equipotent Agonists of Human and Rat GPR35-Reference-Cited by-同舟云学术

The Antiallergic Mast Cell Stabilizers Lodoxamide and Bufrolin as the First High and Equipotent Agonists of Human and Rat GPR35

Published:2013-10-10 Issue:1 Volume:85 Page:91-104
ISSN:0026-895X
Container-title:Molecular Pharmacology
language:en
Short-container-title:Mol Pharmacol

Author:

MacKenzie Amanda E.,Caltabiano Gianluigi,Kent Toby C.,Jenkins Laura,McCallum Jennifer E.,Hudson Brian D.,Nicklin Stuart A.,Fawcett Lindsay,Markwick Rachel,Charlton Steven J.,Milligan Graeme

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference31 articles.

1. A map of human genome variation from population-scale sequencing

2. Ballesteros JA and Weinstein H (1995) Integrated methods for modeling G-protein coupled receptors. Methods Neurosci 366–428.

3. Membrane Protein Simulations Using AMBER Force Field and Berger Lipid Parameters

4. Discovery of 2-(4-Methylfuran-2(5H)-ylidene)malononitrile and Thieno[3,2-b]thiophene-2-carboxylic Acid Derivatives as G Protein-Coupled Receptor 35 (GPR35) Agonists

5. Discovery of Natural Phenols as G Protein-Coupled Receptor-35 (GPR35) Agonists

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of FRET- and BRET-based live-cell biosensors in deorphanization and ligand discovery studies on orphan G protein-coupled receptors;SLAS Discovery;2024-09

2. Mast cell stabilizers: from pathogenic roles to targeting therapies;Frontiers in Immunology;2024-08-01

3. From orphan to oncogene: The role of GPR35 in cancer and immune modulation;Cytokine & Growth Factor Reviews;2024-06

4. Drug-eluting nanofibrous wound dressings composed of polycaprolactone and gelatin augment diabetic wounds healing via reducing oxidative stress and inflammation: An in vitro and in vivo study;Journal of Bioactive and Compatible Polymers;2024-03

5. Metabolite-sensing GPCRs in rheumatoid arthritis;Trends in Pharmacological Sciences;2024-02